Scheffeler and colleagues conducted a study on 4507 NSCLC patients using a NGS panel containing 14 genes, and 53.5% of the mutant KRAS patients had at least one additional mutation, a percentage higher than ours, since KRAS concomitant mutations were observed in eight of 24 mutant samples (33.3%) [27]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.